Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 07/19 07:38:16 pm
71.93 EUR   -0.80%
07/18SANOFI : Revolution, Sanofi partner on SHP-2 inhibitors for cancer
AQ
07/18CanSino latest to file for HKEX IPO
AQ
07/16SANOFI : Disclosure of trading in own shares
GL
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : Positive results for DNA-based Zika Vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:11pm CEST

All 40 healthy volunteers in the study developed Zika-specific antiboides after three doses, researchers said.

The companies GLS-5700 is a DNA-based vaccine that is made by reproducing sections of the Zika virus genome and loading them onto a plasmid, unlike standard vaccines that usually use inactivated or killed versions of a virus.

After the vaccine is injected into a patient, a device is used to generate electrical impulses that create small pores in cells that allow the DNA to get inside.

Sanofi ended development on its more traditional Zika vaccine last month, while Takeda is still working on its own product.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:25pSANOFI : NAD Recommends Chattem Discontinue 'Twice As Fast' Claim for Xyzal Foll..
AQ
10:31aSANOFI : Revolution scores $500M Sanofi deal on first oncology program
AQ
10:29aSANOFI : bags rights to Revolutions SHP2 cancer drug
AQ
10:29aSANOFI : pays $50 million for Revolution Medicines SHP2 inhibitor
AQ
07/18SANOFI : Revolution, Sanofi partner on SHP-2 inhibitors for cancer
AQ
07/18CanSino latest to file for HKEX IPO
AQ
07/17SANOFI : 11th Dengvaxia complaint filed vs. Garin, 36 others
AQ
07/17SANOFI : NBI files raps in Ombudsman vs. Aquino, others over Dengvaxia mess
AQ
07/17NBI TO OMBUDSMAN : Prosecute Noynoy, Abad, Garin, et al. for graft over dengue v..
AQ
07/16SANOFI : Disclosure of trading in own shares
GL
More news
News from SeekingAlpha
07/16Aquestive Therapeutics Readies $60 Million IPO 
07/12Constellation Pharmaceuticals Readies $80 Million IPO Plans 
07/10A Wormhole View Of Voyager's Parkinson's Gene Therapy 
07/10BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Catabasis Nears Phase 3 Start, Regulus Sl.. 
07/09Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growin.. 
Financials (€)
Sales 2018 35 048 M
EBIT 2018 8 298 M
Net income 2018 5 080 M
Debt 2018 15 904 M
Yield 2018 4,15%
P/E ratio 2018 17,42
P/E ratio 2019 16,27
EV / Sales 2018 3,03x
EV / Sales 2019 2,86x
Capitalization 90 118 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 78,2 €
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI0.92%104 422
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225